The 48th Central Research Institute of the Russian Federation Ministry of Defense (CRI 48) has studied the antiviral activity of the drug Kagocel in relation to a new pandemic strain of SARS-CoV-2 in the course of in vitro experiments.
The study was conducted using a pandemic strain of SARS-CoV-2 (COVID-19) obtained in 2020 from FGBU GNTS VB (Federal Budgetary Science Enterprise «State Science Center for Virology and Biotechnology») «Vector» of Rospotrebnadzor, and stored in the specialized collection of the CRI 48 of the RF Ministry of Defense.
The results of the study revealed that the introduction of the drug Kagocel (its pharmaceutical substance) into the corresponding cell culture leads to effective suppression of reproduction of the SARS-CoV-2 virus. The effectiveness of SARS-CoV-2 reproduction suppression demonstrated by Kagocel in those experiments, is consistent with international and Russian standards for «high efficiency antiviral drugs», including the relevant recommendations of Federal Science Budgetary Institution «Center for Expertise of Medical Application Products» under Ministry of Health of Russia.
The study has shown conclusively that the drug Kagocel effectively suppresses the reproduction of the SARS-CoV-2 pandemic coronavirus and therefore can be considered as one of promising candidates for the treatment and prevention of COVID-19. In order to confirm the antiviral activity of the drug Kagocel in relation to the pandemic strain SARS-CoV-2, clinical studies will be conducted on patients in the near future.
«The search for new drugs for COVID-19 therapy is a lengthy and costly process, which is unacceptable in the context of a rapidly developing pandemic for quite objective reasons. The modern medical community expertly selects an effective algorithm for the prevention and treatment of the coronavirus infection. Therefore, the use of antiviral drugs that have an appropriate evidence base on various strains of SARS, which include coronaviruses, especially on the pandemic strain SARS-CoV-2, can significantly increase the effectiveness in the treatment of COVID-19. We are proud of the results of experiments conducted in one of the leading Russian scientific centers of this profile, that have also passed an independent examination. We are convinced that the use of interferon inducers, including Kagocel, will help with choosing the best strategy for the fight against the pandemic,» said Vladimir Nesterenko, head of the Nearmedic group.
The results of the in vitro studies have been published in the Antibiotics and Chemotherapy scientific journal, 2020, 65; No. 3-4, and will be published in June 2020.